The company is significantly advanced the progress of the novel therapy for cardiac amyloidosis, leveraging Attruby. Initial patient data suggests significant improvements for individuals suffering from the severe https://attruby358504.bligblogging.com/42854637/bridgebio-improves-cardiac-amyloidosis-management-with-the-drug